18889881171
Kalkine 0
countryflagUS

Blueprint Medicines Corp

Healthcare US BPMC

100.56USD
-0.95(0.94%)

Last update at 2025-05-22T16:59:00Z

Day Range

99.65101.44
LowHigh

52 Week Range

72.24121.90
LowHigh

Fundamentals

  • Previous Close 101.51
  • Market Cap6007.63M
  • Volume188415
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-262.12899M
  • Revenue TTM434.42M
  • Revenue Per Share TTM6.99
  • Gross Profit TTM 177.28M
  • Diluted EPS TTM-2.09

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -552.28100M -641.08400M 314.94M -347.69400M -236.64200M
Minority interest - - - - -
Net income -557.51700M -644.08500M 313.88M -328.70300M -236.64200M
Selling general administrative 237.37M 195.29M 157.74M 96.39M 47.93M
Selling and marketing expenses - - - - -
Gross profit 186.22M 162.15M 793.31M 66.51M 44.52M
Reconciled depreciation 11.73M 6.48M 6.56M 5.26M 4.25M
Ebit -549.25300M -648.46000M 302.15M -366.58500M -240.81500M
Ebitda -537.51800M -641.98100M 308.71M -361.32600M -236.56900M
Depreciation and amortization 11.73M 6.48M 6.56M 5.26M 4.25M
Non operating income net other 2.00M -1.48900M -0.36600M -0.10000M 10.46M
Operating income -549.25300M -648.46000M 302.15M -366.58500M -247.02800M
Other operating expenses 741.55M 822.06M 485.03M 427.84M 291.55M
Interest expense 16.77M 7.38M 12.79M 13.73M 0.07M
Tax provision 5.24M 3.00M 1.06M - -
Interest income - - - 13.73M 0.07M
Net interest income -16.76700M 2.39M 6.60M 13.73M -0.07300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 5.24M 3.00M 1.06M -18.99100M 10.46M
Total revenue 204.04M 180.08M 793.74M 66.51M 44.52M
Total operating expenses 723.74M 804.13M 484.60M 427.84M 291.55M
Cost of revenue 17.81M 17.93M 0.42M 331.45M 243.62M
Total other income expense net -3.02800M 7.38M 12.79M 18.89M 10.46M
Discontinued operations - - - - -
Net income from continuing ops -557.51700M -644.08500M 313.88M -414.20600M -281.16300M
Net income applicable to common shares -557.51700M -644.08500M 313.88M -347.69400M -236.64200M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1049.25M 1349.90M 1252.22M 1718.39M 707.69M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 33.35M 35.02M -539.46500M -655.85300M 379.44M
Total liab 918.64M 835.23M 281.49M 248.31M 243.34M
Total stockholder equity 130.61M 514.68M 970.74M 1470.09M 464.36M
Deferred long term liab - - - - -
Other current liab 127.99M -295.54600M 96.76M 105.94M 88.71M
Common stock 0.06M 0.06M 0.06M 0.06M 0.05M
Capital stock 0.06M 0.06M 0.06M 0.06M 0.05M
Retained earnings -2339.94200M -1832.95800M -1275.44100M -631.35600M -945.23800M
Other liab - 436.97M 28.41M 35.83M 47.73M
Good will - - - - -
Other assets 0.00000M 26.78M 19.81M 569.29M 15.39M
Cash 71.29M 119.71M 209.95M 684.64M 113.94M
Cash and equivalents - - - - -
Total current liabilities 214.92M 183.23M 149.76M 130.80M 106.48M
Current deferred revenue 0.81M 448.62M 36.58M 12.56M 6.16M
Net debt 702.84M 122.74M -98.54000M -595.03200M -17.98900M
Short term debt 81.41M 27.43M 8.09M 7.93M 6.82M
Short long term debt 30.28M 16.85M - - -
Short long term debt total 774.12M 242.45M 111.41M 89.60M 95.95M
Other stockholder equity 2473.99M 2358.02M 2250.25M 2106.60M 1412.08M
Property plant equipment - 33.34M 30.70M 34.13M 38.36M
Total current assets 808.39M 1046.65M 554.02M 927.76M 516.79M
Long term investments 84.32M 133.48M 557.53M 677.87M 64.41M
Net tangible assets - 514.68M 1247.09M 1470.09M 464.36M
Short term investments 639.36M 825.28M 267.17M 187.21M 369.62M
Net receivables 43.18M 36.94M 37.03M 25.31M 23.41M
Long term debt 208.53M 535.28M - - -
Inventory 21.22M 29.70M 21.82M 8.58M -434.02200M
Accounts payable 4.71M 2.73M 8.33M 4.37M 4.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -3.49500M -10.44300M -4.13300M -5.21400M -2.53500M
Additional paid in capital - - - - -
Common stock total equity - 0.06M 0.06M 0.06M 0.05M
Preferred stock total equity - - - - -
Retained earnings total equity - -1832.95800M -1275.44100M -631.35600M -945.23800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 30.65M 26.78M 19.81M 11.09M 15.39M
Deferred long term asset charges - - - - -
Non current assets total 240.86M 303.25M 698.20M 790.63M 190.91M
Capital lease obligations 93.68M 103.37M 111.41M 89.60M 95.95M
Long term debt total - 535.28M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -140.33200M 35.38M -431.09000M -2.45300M -148.41100M
Change to liabilities 3.55M 10.32M 15.42M 38.43M 24.36M
Total cashflows from investing activities -149.54100M -225.86000M -434.24900M -16.46600M -161.08800M
Net borrowings 553.61M 137.79M 137.79M 137.79M -1.69000M
Total cash from financing activities 561.81M 50.72M 617.76M 340.64M 4.45M
Change to operating activities -31.98600M 1.05M -1.35400M 31.57M 26.01M
Net income -557.51700M -644.08500M 313.88M -347.69400M -236.64200M
Change in cash -90.21500M -474.68500M 570.20M 46.17M -331.64300M
Begin period cash flow 215.12M 689.80M 119.60M 73.43M 405.07M
End period cash flow 124.90M 215.12M 689.80M 119.60M 73.43M
Total cash from operating activities -502.27700M -298.65300M 387.04M -278.01500M -175.00900M
Issuance of capital stock 0.00000M 0.00000M 582.49M 341.04M 6.42M
Depreciation 11.73M 6.48M 6.56M 5.26M 4.25M
Other cashflows from investing activities -0.29000M -258.15200M -258.15200M -2.45300M -148.41100M
Dividends paid - - - - -
Change to inventory -8.92200M -12.56100M -6.70700M 8.97M -6.70700M
Change to account receivables 1.57M -18.14300M -6.38700M -0.59900M 0.20M
Sale purchase of stock - - 79.31M 340.75M 6.14M
Other cashflows from financing activities 561.81M 50.72M 35.27M -0.40000M -0.28100M
Change to netincome 117.39M 95.01M 75.95M 54.65M 30.53M
Capital expenditures 8.92M 261.24M 3.16M 14.01M 12.68M
Change receivables 1.57M -18.14300M -6.38700M -0.59900M -
Cash flows other operating -70.08900M 264.33M -11.69000M -28.06200M 2.50M
Exchange rate changes - - - - -
Cash and cash equivalents changes -90.00800M -473.79700M 570.54M 46.16M -331.64300M
Change in working capital -53.76900M -23.68000M -15.61800M 9.72M 31.24M
Stock based compensation 98.97M 91.63M 75.53M 54.65M 30.53M
Other non cash items -1.69700M 269.64M 6.22M 4.99M -4.38700M
Free cash flow -511.19600M -559.89400M 383.88M -292.02800M -187.68600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BPMC
Blueprint Medicines Corp		 -0.95 0.94% 100.56 - - 13.83 19.47 13.43 -11.2158
NVO
Novo Nordisk A/S		 -0.155 0.23% 68.05 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.95 1.40% 68.95 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.41 1.01% 430.91 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -10.3 1.70% 594.32 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Blueprint Medicines Corp

45 Sidney Street, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Mr. Jeffrey W. Albers J.D., M.B.A., MBA Exec. Chairman 1971
Ms. Kathryn Haviland Pres, CEO & Director 1976
Mr. Alexis A. Borisy A.M. Co-Founder & Director 1972
Mr. Michael Landsittel Chief Financial Officer 1972
Dr. Percy H. Carter M.B.A., Ph.D. Chief Scientific Officer 1971
Dr. Fouad Namouni M.D. Pres of R&D 1969
Ms. Christina Rossi Chief Operating Officer 1976
Dr. Christopher K. Murray Sr. VP of Technical Operations 1963
Jenna Cohen Sr. Director & Head of Investor Relations NA
Ms. Tracey L. McCain Esq. Exec. VP, Chief Legal & Compliance Officer and Sec. 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.